

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623SQS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *
* *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	STN Patent Forums to be held in June 2005

NEWS 20 JUN 06 The Analysis Edition of STN Express with Discover!
 (Version 8.0 for Windows) now available

NEWS 21 JUN 13 RUSSIAPAT: New full-text patent database on STN

NEWS 22 JUN 13 FRFULL enhanced with patent drawing images

NEWS 23 JUN 20 MEDICONF to be removed from STN

NEWS 24 JUN 27 MARPAT displays enhanced with expanded G-group
 definitions
 and text labels

NEWS 25 JUL 01 MEDICONF removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
 MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 19:25:58 ON 05 JUL 2005

=> File Medline EMBASE Biosis Caplus
 COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 19:26:07 ON 05 JUL 2005

FILE 'EMBASE' ENTERED AT 19:26:07 ON 05 JUL 2005
 COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 19:26:07 ON 05 JUL 2005
 Copyright (c) 2005 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 19:26:07 ON 05 JUL 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> s kinase (2A) inhibitor
L1 140201 KINASE (2A) INHIBITOR

=> s kinase (3A) transfection
L2 742 KINASE (3A) TRANSFECTION

=> s l1 and l2 and phosphorylation
L3 74 L1 AND L2 AND PHOSPHORYLATION

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l3
DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L3
L4 35 DUPLICATE REMOVE L3 (39 DUPLICATES REMOVED)

=> d l4 1-35 bib ab

L4 ANSWER 1 OF 35 MEDLINE on STN DUPLICATE 1
AN 2005232469 IN-PROCESS
DN PubMed ID: 15743775
TI Protein kinase C activates human lipocalin-type prostaglandin D synthase
gene expression through de-repression of notch-HES signaling and enhancement of AP-2beta function in brain-derived TE671 cells.
AU Fujimori Ko; Kadoyama Keiichi; Urade Yoshihiro
CS Department of Molecular Behavioral Biology, Osaka Bioscience Institute,
6-2-4 Furuedai, Suita, Osaka 565-0874, Japan.
SO Journal of biological chemistry, (2005 May 6) 280 (18) 18452-61.
Electronic Publication: 2005-03-02.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20050504
Last Updated on STN: 20050517
AB Here we investigated the regulatory mechanism of lipocalin-type prostaglandin D synthase (L-PGDS) gene expression in human TE671 (medulloblastoma of cerebellum) cells. Reporter analysis of the promoter region from -730 to +75 of the human L-PGDS gene demonstrated that deletion or mutation of the N-box at -337 increased the promoter activity 220-300%. The N-box was bound by Hes-1, a mammalian homologue of Drosophila Hairy and enhancer of split, as examined by electrophoretic mobility shift assay and chromatin immunoprecipitation assay. Functional

expression of the Notch intracellular domain significantly increased Hes-1 expression and decreased L-PGDS expression level in TE671 cells. Moreover, knock-down of Hes-1 mRNA by RNA interference significantly enhanced the L-PGDS mRNA level, indicating that the L-PGDS gene expression is repressed by the Notch-Hes signaling. When the AP-2 element at -98 of the promoter region was deleted or mutated, the promoter activity was drastically decreased to approximately 10% of normal. The AP-2 element was bound by AP-2beta dominantly expressed in TE671 cells, according to the results of electrophoretic mobility shift assay and chromatin immunoprecipitation assay. L-PGDS expression was induced by 12-O-tetradecanoylphorbol-13-acetate in TE671 cells, and this induction was inhibited by a protein **kinase C inhibitor**. Stimulation of TE671 cells with 12-O-tetradecanoylphorbol-13-acetate or **transfection** with protein **kinase** Calpha expression vector induced **phosphorylation** of Hes-1, inhibition of DNA binding of Hes-1 to the N-box, and activation of the AP-2beta function to up-regulate L-PGDS gene expression. These results reveal a novel transcriptional regulatory mechanism responsible for the high level expression of the human L-PGDS gene in TE671 cells.

L4 ANSWER 2 OF 35 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

AN 2005172674 EMBASE

TI The pro-inflammatory mediator leukotriene D(4) induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells.

AU Paruchuri S.; Broom O.; Dib K.; Sjolander A.

CS A. Sjolander, Dept. of Laboratory Medicine, Lund University, Malmo

University Hospital, Entrance 78, SE-205 02 Malmo, Sweden.
anita.sjolander@exppat.mas.lu.se

SO Journal of Biological Chemistry, (8 Apr 2005) Vol. 280, No. 14, pp.

13538-13544.

Refs: 41

ISSN: 0021-9258 CODEN: JBCHA3

CY United States

DT Journal; Article

FS 005 General Pathology and Pathological Anatomy

016 Cancer
048 Gastroenterology

LA English

SL English

ED Entered STN: 20050519

Last Updated on STN: 20050519

AB Inflammatory bowel diseases are associated with increased risk of developing colon cancer. A possible role of the pro-inflammatory leukotriene D(4) (LTD(4)) in this process has been implicated by the

findings that LTD(4) can signal increased proliferation and survival, both

hallmarks of a cancer cell, in non-transformed intestinal epithelial

cells. Here we make the novel finding that LTD(4) can also signal

increased motility in these cells. In parallel, we found that LTD(4)

induced a simultaneous transient 10-fold increase in Rac but not Cdc42

activity. These data were also supported by the ability of LTD(4) to

activate the Rac GDP/GTP exchange factor Vav2. Further, LTD(4) triggered

a 3-fold transient increase in phosphatidylinositol 3-kinase (PI3K)

phosphorylation, a possible upstream activator of the Vav2/Rac signaling pathway. The activation of Rac was blocked by the PI3K inhibitors LY294002 and wortmannin and by **transfection** of a **kinase**-negative mutant of PI3K or a dominant-negative form of Vav2. Furthermore, Rac was found to co-localize with actin in

LTD

(4)-generated membrane ruffles that were formed by a PI3K-dependent

mechanism. In accordance, the inhibition of the PI3K and Rac signaling

pathway also blocked the LTD(4)-induced migration of the intestinal cells.

The present data reveal that an inflammatory mediator such as LTD(4)

cannot only increase proliferation and survival of non-transformed

intestinal epithelial cells but also, via a PI3K/Rac signaling pathway,

trigger a motile response in such cells. These data demonstrate the

capacity of inflammatory mediators to participate in the process by which

inflammatory bowel conditions increase the risk for colon cancer development. .COPYRG. 2005 by The American Society for

Biochemistry and

Molecular Biology, Inc.

L4 ANSWER 3 OF 35 MEDLINE on STN DUPLICATE 2
 AN 2005208403 MEDLINE
 DN PubMed ID: 15843032
 TI Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK.
 AU Jo Chulman; Kim Hyuck; Jo Inho; Choi Insun; Jung Sung-Chul; Kim Joon; Kim Sung Soo; Jo Sangmee Ahn
 CS Department of Biomedical Sciences, National Institute of Health, Seoul, South Korea.
 SO Biochimica et biophysica acta, (2005 Apr 15) 1743 (3) 187-97. Electronic
 Publication: 2004-12-08.
 Journal code: 0217513. ISSN: 0006-3002.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200506
 ED Entered STN: 20050422
 Last Updated on STN: 20050610
 Entered Medline: 20050609
 AB Leukemia inhibitory factor (LIF) is a multifunctional cytokine belonging to the interleukin-6 family and has been shown to stimulate regeneration of injured skeletal muscle. Although LIF has been shown to stimulate muscle cell proliferation, its precise role in differentiation is unclear. Thus, we examined the effect of LIF on the differentiation of cultured C2C12 myoblast cells. In this study, we used both non-glycosylated LIF expressed in bacteria and glycosylated LIF secreted from NIH3T3 cells infected with Ad-LIF. Both non-glycosylated and glycosylated LIF blocked differentiation of myoblasts as measured by expression of myosin heavy chain and myotube formation. Treatment of myoblasts with LIF induced **phosphorylation** of ERK, and the LIF-induced inhibitory effect on myogenesis was blocked by pretreatment with U0126, a specific MEK inhibitor, and transient transfection with dominant negative (DN)-MEK1. In contrast, although LIF activated STAT3, the LIF-induced repression of the MCK transcriptional activity was not reversed by pretreatment with

AG490, a specific Jak **kinase inhibitor** or transient **transfection** with DN-STAT3. Additionally, LIF exhibited its inhibitory effect on myogenesis only when cells were treated at earlier than 12 h after inducing differentiation. Taken together, these results suggest that LIF strongly inhibited early myogenic differentiation though activation of the ERK signaling pathway and its effect is irrespective of glycosylation.

L4 ANSWER 4 OF 35 MEDLINE on STN DUPLICATE 3
 AN 2004319053 MEDLINE
 DN PubMed ID: 15123725
 TI Hepatic nuclear factor 3 and nuclear factor 1 regulate 5-aminolevulinate synthase gene expression and are involved in insulin repression.
 AU Scassa Maria E; Guberman Alejandra S; Ceruti Julieta M; Canepa Eduardo T
 CS Laboratorio de Biologia Molecular, Departamento de Quimica Biologica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellon II Piso 4, Ciudad Universitaria, 1428 Buenos Aires, Argentina.
 SO Journal of biological chemistry, (2004 Jul 2) 279 (27) 28082-92. Electronic Publication: 2004-04-28. Journal code: 2985121R. ISSN: 0021-9258.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200408
 ED Entered STN: 20040629 Last Updated on STN: 20040812 Entered Medline: 20040811
 AB Although the negative regulation of gene expression by insulin has been widely studied, the transcription factors responsible for the insulin effect are still unknown. The purpose of this work was to explore the molecular mechanisms involved in the insulin repression of the 5-aminolevulinate synthase (ALAS) gene. Deletion analysis of the 5'-regulatory region allowed us to identify an insulin-responsive region located at -459 to -354 bp. This fragment contains a highly homologous insulin-responsive (IRE) sequence. By transient transfection assays, we determined that hepatic nuclear factor 3 (HNF3) and nuclear factor 1 (NF1)

are necessary for an appropriate expression of the ALAS gene. Insulin overrides the HNF3beta or HNF3beta plus NF1-mediated stimulation of ALAS transcriptional activity. Electrophoretic mobility shift assay and Southwestern blotting indicate that HNF3 binds to the ALAS promoter. Mutational analysis of this region revealed that IRE disruption abrogates insulin action, whereas mutation of the HNF3 element maintains hormone responsiveness. This dissociation between HNF3 binding and insulin action suggests that HNF3beta is not the sole physiologic mediator of insulin-induced transcriptional repression. Furthermore, Southwestern blotting assay shows that at least two polypeptides other than HNF3beta can bind to ALAS promoter and that this binding is dependent on the integrity of the IRE. We propose a model in which insulin exerts its negative effect through the disturbance of HNF3beta binding or transactivation potential, probably due to specific **phosphorylation** of this transcription factor by Akt. In this regard, results obtained from **transfection** experiments using **kinase inhibitors** support this hypothesis. Due to this event, NF1 would lose accessibility to the promoter. The posttranslational modification of HNF3 would allow the binding of a protein complex that recognizes the core IRE. These results provide a potential mechanism for the insulin-mediated repression of IRE-containing promoters.

L4 ANSWER 5 OF 35 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

AN 2004411440 EMBASE

TI PKC α induces differentiation through ERK1/2 **phosphorylation** in mouse keratinocytes.

AU Seo H.R.; Kwan Y.-W.; Cho C.-K.; Bae S.; Lee S.-J.; Soh J.-W.; Chung H.-Y.; Lee Y.-S.

CS Y.-S. Lee, Laboratory of Radiation Effect, Korea Inst. of Radiol. and Med.

Sci., 215-4 Gongneung-dong, Nowon-Ku, Seoul 139-706, Korea, Republic of.

yslee@kcch.re.kr

SO Experimental and Molecular Medicine, (31 Aug 2004) Vol. 36, No. 4, pp.

292-299.

Refs: 41

ISSN: 1226-3613 CODEN: EMMEF3

CY Korea, Republic of

DT Journal; Article

FS 029 Clinical Biochemistry

LA English

SL English

ED Entered STN: 20041018

Last Updated on STN: 20041018

AB Epidermal keratinocyte differentiation is a tightly regulated stepwise

process that requires protein kinase C (PKC) activation.

Studies on

cultured mouse keratinocytes induced to differentiate with

Ca(2+) have

indirectly implicated the involvement of PKC α isoform. When PKC α was overexpressed in undifferentiated keratinocytes using adenoviral system, expressions of differentiation markers such as loricrin, filaggrin, keratin 1 (MK1) and keratin 10 (MK10) were increased,

and ERK1/2 **phosphorylation** was concurrently induced without change of other MAPK such as p38 MAPK and JNK1/2. Similarly, **transfection** of PKC α **kinase** active mutant (PKC α -CAT) in the undifferentiated keratinocyte, but not PKC β -CAT, also increased differentiation marker expressions.

On the

other hand, PKC α dominant negative mutant (PKC β -KR) reduced Ca(2+)-mediated differentiation marker expressions, while

PKC β -KR did

not, suggesting that PKC α is responsible for keratinocyte differentiation. When downstream pathway of PKC α in

Ca(2+)-mediated

differentiation was examined, ERK1/2, p38 MAPK and JNK1/2 **phosphorylations** were increased by Ca(2+) shift. Treatment of keratinocytes with PD98059, MEK inhibitor, and SB20358, p38 MAPK inhibitor, before Ca(2+) shift induced morphological changes and reduced

expressions of differentiation markers, but treatment with

SP60012, JNK1/2

inhibitor, did not change at all. Dominant negative mutants of

ERK1/2 and

p38 MAPK also inhibited the expressions of differentiation marker expressions in Ca(2+) shifted cells. The above results indicate

that both

ERK1/2 and p38 MAPK may be involved in Ca(2+)-mediated

differentiation,

and that only ERK1/2 pathway is specific for PKC α -mediated differentiation in mouse keratinocytes.

on STN

AN 2004128156 EMBASE

TI Myosin light chain **phosphorylation** and pulmonary endothelial cell hyperpermeability in burns.

AU Tinsley J.H.; Teasdale N.R.; Yuan S.Y.

CS J.H. Tinsley, Dept. of Medical Physiology, TX A/M Univ. Syst. Hlth. Sci.
 Ctr., 702 SW HK Dodgen Loop, Temple, TX 76504, United States.
 jht@tamu.edu

SO American Journal of Physiology - Lung Cellular and Molecular Physiology,
 (2004) Vol. 286, No. 4 30-4, pp. L841-L847.
 Refs: 32
 ISSN: 1040-0605 CODEN: APLPE7

CY United States

DT Journal; Article

FS 005 General Pathology and Pathological Anatomy
 015 Chest Diseases, Thoracic Surgery and Tuberculosis
 037 Drug Literature Index

LA English

SL English

ED Entered STN: 20040422
 Last Updated on STN: 20040422

AB Major cutaneous burns result in not only localized tissue damage but broad
 systemic inflammation causing organ system damage distal to the burn site.
 It is well recognized that many problems result from the release of
 inflammatory mediators that target vascular endothelial cells, causing
 organ dysfunction. The pulmonary microvessels are particularly susceptible to functional abnormalities as a direct consequence of
 exposure to burn-induced inflammatory mediators. Traditional therapeutic
 intervention is quite often ineffective in treating burn patients suffering from systemic problems. A possible explanation for this
 ineffectiveness may be that because so many mediators are released,
 supposedly activating numerous signaling cascades that interact with each
 other, targeting of upstream factors in these cascades on an individual
 basis becomes futile. Therefore, if an end-point effector responsible for
 endothelial dysfunction following burn injury could be identified, it may
 present a target for intervention. In this study, we identified **phosphorylation** of myosin light chain (MLC) as a required element of burn plasma-induced hyperpermeability across rat lung microvascular

endothelial cell monolayers. In addition, pharmacological inhibition of myosin light chain kinase (MLCK) and Rho **kinase** as well as **transfection** of MLCK-inhibiting peptide blocked actin stress fiber formation and MLC **phosphorylation** in response to burn plasma. The results suggest that blocking MLC **phosphorylation** may provide therapeutic intervention in burn patients with the goal of alleviating systemic inflammation-induced endothelial dysfunction.

L4 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:42090 CAPLUS

DN 138:100897

TI Use of tyrosine **kinase inhibitors** for treating inflammatory bowel diseases (IBD)

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
PI	WO 2003004007	A2	20030116	WO 2002-IB3317
20020628	WO 2003004007	A3	20030828	
CH, CN,	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,			
GE, GH,	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,			
LK, LR,	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,			
OM, PH,	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,			
TT, TZ,	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR,			
	UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
AZ, BY,	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			
FR, GB,	KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI,			
CM, GA,	GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI,			
	GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2452392	AA	20030116	CA 2002-2452392	
20020628	EP 1401416	A2	20040331	EP 2002-758697
20020628				

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004537542 T2 20041216 JP 2003-510018
20020628

US 2004266801 A1 20041230 US 2004-482033
20040707

PRAI US 2001-301405P P 20010629

WO 2002-IB3317 W 20020628

OS MARPAT 138:100897

AB The present invention relates to a method for treating
inflammatory bowel

diseases (IBD), such as Crohn's disease, comprising
administering a
tyrosine **kinase inhibitor** to a human in need of such
treatment, more particularly a non-toxic, selective and potent
c-kit

inhibitor. Preferably, said inhibitor is unable to promote
death of IL-3

dependent cells cultured in presence of IL-3.

L4 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:22675 CAPLUS

DN 138:95588

TI Use of tyrosine **kinase inhibitors** for treating
multiple sclerosis

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.
--	------------	------	------	-----------------

DATE

PI	WO 2003002107	A2	20030109	WO 2002-IB3298
----	---------------	----	----------	----------------

20020628

	WO 2003002107	A3	20031002	
--	---------------	----	----------	--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
OM, PH,

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR,
TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI,
FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI,
CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2452167 AA 20030109 CA 2002-2452167

20020628

EP 1401414 A2 20040331 EP 2002-758692

20020628

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2005502614 T2 20050127 JP 2003-508346

20020628

US 2004259892 A1 20041223 US 2003-482034

20031229

PRAI US 2001-301409P P 20010629

WO 2002-IB3298 W 20020628

OS MARPAT 138:95588

AB The present invention relates to a method for treating Multiple
Sclerosis

(MS) comprising administering a tyrosine **kinase**
inhibitor to a human in need of such treatment, more particularly
a non-toxic, selective and potent c-kit inhibitor. Preferably

said

inhibitor is unable to promote death of IL-3 dependent cells
cultured in
presence of IL-3.

L4 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:22674 CAPLUS

DN 138:83364

TI Use of tyrosine kinase inhibitions for treating allergic diseases

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

PATENT NO. KIND DATE APPLICATION NO.

DATE

PI WO 2003002106 A2 20030109 WO 2002-IB3297

20020628

WO 2003002106 A3 20030530

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR,

OM, PH, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
 TT, TZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR,
 RW: UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 AZ, BY, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 FR, GB, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI,
 CM, GA, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2452371 AA 20030109 CA 2002-2452371

20020628

EP 1401413 A2 20040331 EP 2002-755512

20020628

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
 MC, PT,

JP 2004537536 T2 20041216 JP 2003-508345
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

20020628

US 2004259893 A1 20041223 US 2003-482035

20031229

PRAI US 2001-301408P P 20010629

WO 2002-IB3297 W 20020628

OS MARPAT 138:83364

AB The present invention relates to a method for treating allergic
 diseases

such as asthma, comprising administering a tyrosine **kinase**
inhibitor to a human in need of such treatment, more particularly
 a non-toxic, selective and potent c-kit inhibitor. Preferably,

said

inhibitor is unable to promote death of IL-3 dependent cells
 cultured in
 presence of IL-3.

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:22673 CAPLUS

DN 138:95587

TI Use of tyrosine **kinase inhibitors** for treating bone
 loss

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

PATENT NO. KIND DATE APPLICATION NO.

DATE

PI WO 2003002105 A2 20030109 WO 2002-IB3288
 20020628
 WO 2003002105 A3 20030828
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
 CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
 GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
 OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR,
 TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI,
 FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI,
 CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2452390 AA 20030109 CA 2002-2452390
 20020628

EP 1401411 A2 20040331 EP 2002-755506
 20020628
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
 MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004530722 T2 20041007 JP 2003-508344
 20020628

US 2004266771 A1 20041230 US 2004-482036
 20040713

PRAI US 2001-301411P P 20010629
 WO 2002-IB3288 W 20020628

OS MARPAT 138:95587

AB The present invention relates to a method for treating bone loss
 such as
 osteoporosis comprising administering a tyrosine **kinase**
inhibitor to a human in need of such treatment, more particularly
 a non-toxic, selective and potent c-kit inhibitor. Preferably,
 said
 inhibitor is unable to promote death of IL-3 dependent cells
 cultured in
 presence of IL-3.

L4 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:536960 CAPLUS

DN 139:163424

TI T-cell-derived Interleukin-17 Regulates the Level and Stability
 of

Cyclooxygenase-2 (COX-2) mRNA through Restricted Activation of
 the p38

Mitogen-activated Protein Kinase Cascade: Role of Distal Sequences in the

3'-Untranslated Region of COX-2 mRNA

AU Faour, Wissam H.; Mancini, Arturo; He, Qing Wen; Di Battista, John A.

CS Molecular Biology Program, University of Montreal, Montreal, QC, H3A 1A1, Can.

SO Journal of Biological Chemistry (2003), 278(29), 26897-26907
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB Although interleukin-17 (IL-17) is the pre-eminent T-cell-derived pro-inflammatory cytokine, its cellular mechanism of action remains poorly

understood. The authors explored novel signaling pathways mediating IL-17

induction of the cyclooxygenase-2 (COX-2) gene in human chondrocytes,

synovial fibroblasts, and macrophages. In preliminary work, recombinant

human (rh) IL-17 stimulated a rapid (5-15 min), substantial (>8-fold), and

sustained (>24 h) increase in COX-2 mRNA, protein, and prostaglandin E2

release. Screening expts. with cell-permeable **kinase inhibitors** (e.g. SB202190 and p38 inhibitor), Western anal. using specific anti-phospho-antibodies to a variety of

mitogen-activated protein

kinase cascade intermediates, co-**transfection** studies

using chimeric cytomegalovirus-driven constructs of GAL4

DNA-binding

domains fused to the transactivation domains of transcription factors

together with Gal-4 binding element-luciferase reporters, ectopic overexpression of activated protein kinase expression plasmids

(e.g.

MKK3/6), or transfection expts. with wild-type and mutant COX-2 promoter

constructs revealed that rhIL-17 induction of the COX-2 gene was mediated

exclusively by the stress-activated protein kinase 2/p38 cascade. A

rhIL-17-dependent transcriptional pulse (1.76-fold induction) was initiated by ATF-2/CREB-1 transactivation through the ATF/CRE

enhancer

site in the proximal promoter. However, steady-state levels of rhIL-17-induced COX-2 mRNA declined rapidly (<2 h) to control

levels under

wash-out conditions. Adding rhIL-17 to transcriptionally arrested cells

stabilized COX-2 mRNA for up to 6 h, a process compromised by SB202190.

Deletion anal. using transfected chimeric luciferase-COX-2 mRNA 3'-untranslated region reporter constructs revealed that rhIL-17 increased

reporter gene mRNA stability and protein synthesis via distal regions

(-545 to -1414 bases) of the 3'-untranslated region. This response was

mediated entirely by the stress-activated protein kinase 2/p38 cascade.

As such, IL-17 can exert direct transcriptional and post-transcriptional

control over target proinflammatory cytokines and oncogenes.

RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 35 MEDLINE on STN DUPLICATE 4
AN 2003304429 MEDLINE
DN PubMed ID: 12730223
TI Fibronectin fragment activation of proline-rich tyrosine kinase
PYK2
mediates integrin signals regulating collagenase-3 expression by
human
chondrocytes through a protein kinase C-dependent pathway.
AU Loeser Richard F; Forsyth Christopher B; Samarel Allen M; Im
Hee-Jeong
CS Department of Internal Medicine, Rush Medical College,
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois
60612,
USA.. rloeser@rush.edu
NC AR49003 (NIAMS)
HL63711 (NHLBI)
P50-AR39239 (NIAMS)
SO Journal of biological chemistry, (2003 Jul 4) 278 (27) 24577-85.
Electronic Publication: 2003-04-30.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200308
ED Entered STN: 20030701
Last Updated on STN: 20030819
Entered Medline: 20030818
AB Fibronectin fragments (FN-f), including the 110-kDa fragment
that binds
the alpha5beta1 integrin, stimulate collagenase-3 (MMP-13)
production and
cartilage destruction. In the present study, treatment of
chondrocytes
with the 110-kDa FN-f or an activating antibody to the
alpha5beta1

integrin was found to increase tyrosine autophosphorylation (Tyr-402) of the proline-rich tyrosine kinase-2 (PYK2) without significant change in autophosphorylation (Tyr-397) of focal adhesion kinase (FAK). The tyrosine **kinase inhibitor** tyrphostin A9, shown previously to block a PYK2-dependent pathway, blocked the FN-f-stimulated increase in MMP-13, whereas tyrphostin A25 did not. FN-f-stimulated PYK2 **phosphorylation** and MMP-13 production was also blocked by reducing intracellular calcium levels. Adenovirally mediated overexpression of wild type but not mutant PYK2 resulted in increased MMP-13 production. The protein kinase C (PKC) activator phorbol 12-myristate 13-acetate stimulated PYK2 **phosphorylation** and MMP-13 production. MMP-13 expression stimulated by either phorbol 12-myristate 13-acetate or FN-f was blocked by PKC inhibitors including the PKCdelta inhibitor rottlerin. Furthermore, PKCdelta translocation from cytosol to membrane was noted within 5 min of stimulation with FN-f. Immortalized human chondrocytes, transiently transfected with MMP-13 promoter-luciferase reporter constructs, showed increased promoter activity after FN-f treatment that was inhibited by co-transfection with either of two dominant negative mutants of PYK2 (Y402F and K457A). No inhibition was seen after cotransfection with wild type PYK2, a dominant negative of FAK (FRNK) or empty vector plasmid. FN-f-stimulated MMP-13 promoter activity was also inhibited by chemical inhibitors of ERK, JNK, and p38 mitogen-activated protein (MAP) **kinases** or by co-transfection of dominant negative MAP kinase mutant constructs. These studies have identified a novel pathway for the MAP kinase regulation of MMP-13 production which involves FN-f stimulation of the alpha5beta1 integrin and activation of the nonreceptor tyrosine kinase PYK2 by PKC, most likely PKCdelta

AN 2003040930 MEDLINE
 DN PubMed ID: 12431978
 TI Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen.
 AU Haynes M Page; Li Lei; Sinha Diviya; Russell Kerry S; Hisamoto Koji; Baron Roland; Collinge Mark; Sessa William C; Bender Jeffrey R
 CS Section of Cardiovascular Medicine, Department of Pharmacology, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Connecticut 06536, USA.
 NC HL61782 (NHLBI)
 SO Journal of biological chemistry, (2003 Jan 24) 278 (4) 2118-23. Electronic Publication: 2002-11-12. Journal code: 2985121R. ISSN: 0021-9258.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200303
 ED Entered STN: 20030129
 Last Updated on STN: 20030305
 Entered Medline: 20030304
 AB 17beta-Estradiol activates endothelial nitric oxide synthase (eNOS), enhancing nitric oxide (NO) release from endothelial cells via the phosphatidylinositol 3-kinase (PI3-kinase)/Akt pathway. The upstream regulators of this pathway are unknown. We now demonstrate that 17beta-estradiol rapidly activates eNOS through Src kinase in human endothelial cells. The Src family **kinase specific-inhibitor** 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) abrogates 17beta-estradiol- but not ionomycin-stimulated NO release. Consistent with these results, PP2 blocked 17beta-estradiol-induced Akt **phosphorylation** but did not inhibit NO release from cells transduced with a constitutively active Akt. PP2 abrogated 17beta-estradiol-induced activation of PI3-kinase, indicating that the PP2-inhibitable kinase is upstream of PI3-kinase and Akt. A 17beta-estradiol-induced estrogen receptor/c-Src association correlated with rapid c-Src **phosphorylation**. Moreover, **transfection** of **kinase-dead** c-Src inhibited 17beta-estradiol-induced Akt **phosphorylation**, whereas constitutively active c-Src increased basal Akt **phosphorylation**. Estrogen stimulation of murine embryonic fibroblasts with homozygous

deletions of the c-src, fyn, and yes genes failed to induce Akt **phosphorylation**, whereas cells maintaining c-Src expression demonstrated estrogen-induced Akt activation. Estrogen rapidly activated c-Src inducing an estrogen receptor, c-Src, and P85 (regulatory subunit of PI3-kinase) complex formation. This complex formation results in the successive activation of PI3-kinase, Akt, and eNOS with consequent enhanced NO release, implicating c-Src as a critical upstream regulator of the estrogen-stimulated PI3-kinase/Akt/eNOS pathway.

L4 ANSWER 14 OF 35 MEDLINE on STN DUPLICATE 6
AN 2003361838 MEDLINE
DN PubMed ID: 12824296
TI Arg-Gly-Asp-Ser (RGDS) peptide stimulates transforming growth factor beta1 transcription and secretion through integrin activation.
AU Ortega-Velazquez R; Diez-Marques M L; Ruiz-Torres M P; Gonzalez-Rubio M; Rodriguez-Puyol M; Rodriguez Puyol D
CS Department of Physiology, Alcala University, Nephrology Section, Hospital Principe de Asturias, and IRSIN, Madrid, Spain.
SO FASEB journal : official publication of the Federation of American Societies for Experimental Biology, (2003 Aug) 17 (11) 1529-31. Electronic Publication: 2003-06-03. Journal code: 8804484. ISSN: 1530-6860.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200308
ED Entered STN: 20030805
Last Updated on STN: 20030812
Entered Medline: 20030811
AB Extracellular matrix (ECM) components, through specific peptide motifs such as Arg-Gly-Asp (RGD), interact with integrins and can modify the behavior of cells. Transforming growth factor-beta1 (TGF-beta1) is the main cytokine involved in the synthesis of ECM proteins. We analyzed the effect of a RGD-containing peptide, as Arg-Gly-Asp-Ser (RGDS), on the regulation of TGF-beta1 secretion in cultured human mesangial cells. We found that RGDS increased mRNA expression and secretion of TGF-beta1 by

stimulating the TGF-beta1 gene promoter. This effect was dependent on the interaction of RGDS with integrins. We evaluated the signaling pathways implicated in TGF-beta1 production by analyzing the effect of RGDS on kinase-related integrins. RGDS stimulated tyrosine **phosphorylation** as well as integrin-linked kinase (ILK) activity. However, tyrosine **kinase inhibitors** did not prevent the RGDS effect. In contrast, the inhibition of ILK by cell **transfection** with a **kinase** dead-ILK completely abolished the increased TGF-beta1 secretion and promoter activity in the presence of RGDS. Thus RGDS modulates the secretion of TGF-beta1, probably through increased synthesis by interacting with integrins and activating ILK. This supports a role for ECM components in the regulation of their own secretion.

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:87759 CAPLUS

DN 138:351913

TI ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells

AU Lee, Ming-Shyue; Igawa, Tsukasa; Yuan, Ta-Chun; Zhang, Xiu-Qing; Lin,

Fen-Fen; Lin, Ming-Fong

CS Department of Biochemistry and Molecular Biology, University of Nebraska

Medical Center, Omaha, NE, 68198, USA

SO Oncogene (2003), 22(5), 781-796

CODEN: ONCNES; ISSN: 0950-9232

PB Nature Publishing Group

DT Journal

LA English

AB The expression and secretion of prostate-specific antigen (PSA) are

regulated by androgens in normal prostate secretory epithelial cells. In

prostate cancer patients, the serum PSA level is usually elevated and

cancer cells are initially responsive to androgens. However, those cancer

cells become androgen-independent after androgen ablation therapy. In

hormone-refractory cancer patients, even in an androgen-deprived environment, the circulation level of PSA rebounds and is

constitutively

elevated through a yet unknown mechanism. Tyrosine **phosphorylation** of ErbB-2 is involved in regulating the

androgen-responsive phenotype of prostate cancer cells, and it is at least partly regulated by the cellular form of prostatic acid phosphatase (PACP), a prostate-unique protein tyrosine phosphatase. We investigated the ErbB-2 signal pathway in androgen-independent PSA secretion. LNCaP C-81 cells, which are androgen-independent LNCaP cells lacking endogenous PACP expression with a hyper-tyrosine phosphorylated ErbB-2, secreted a higher level of PSA in conditioned media than did androgen-sensitive LNCaP C-33 parental cells. A restored expression of cellular PACP in C-81 cells was concurrent with a decrease in tyro-**phosphorylation** of ErbB-2 and reduction of PSA secretion. Moreover, transient transfection of C-33 cells with the wild-type ErbB-2 or a constitutively active mutant of MEK1 cDNA resulted in an increased level of secreted PSA. The elevation of secreted PSA level by the forced expression of ErbB-2 was inhibited by an MEK inhibitor, PD98059. In C-81 cells, the expression of a dominant neg. mutant of ErbB-2 reduced the secreted level of PSA. The inhibition of ErbB-2 or mitogen-activated protein (MAP) **kinases** by specific **inhibitors** AG879, AG825, or PD98059 led to a decrease in PSA secretion. Taken together, our data clearly indicate that the ErbB-2 signal pathway via MAP kinases (ERK1/2) is involved in regulating the secretion of PSA by androgen-independent human prostate cancer LNCaP C-81 cells in an androgen-depleted environment.

RE.CNT 74 THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 35 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

DUPLICATE 7

AN 2003084542 EMBASE

TI Altered protein kinase C (PKC) isoforms in non-small cell lung cancer

cells: PKCδ promotes cellular survival and chemotherapeutic resistance.

AU Clark A.S.; West K.A.; Blumberg P.M.; Dennis P.A.

CS P.A. Dennis, Cancer Therapeutics Branch, National Cancer Institute,

Building 8, 8901 Wisconsin Avenue, Bethesda, MD 20889, United States.

pdennis@nih.gov

SO Cancer Research, (15 Feb 2003) Vol. 63, No. 4, pp. 780-786.

Refs: 36

ISSN: 0008-5472 CODEN: CNREA8

CY United States

DT Journal; Article

FS 016 Cancer

037 Drug Literature Index

LA English

SL English

ED Entered STN: 20030313

Last Updated on STN: 20030313

AB Drugs that target protein kinase C (PKC) are now being evaluated in

patients with non-small cell lung cancer (NSCLC), but the role of PKC in

NSCLC cells remains unclear. We report here that NSCLC cell lines show

enhanced **phosphorylation** and altered expression of specific PKC isoforms compared with normal lung epithelial cells. PKC inhibition

variably increased apoptosis, with rottlerin, a PKC δ inhibitor, being most effective and potentiating chemotherapy-induced apoptosis,

especially with trastuzumab. Consistent with PKC δ being anti-apoptotic in NSCLC cells, transient **transfection** of a **kinase**-dead mutant of PKC δ increased apoptosis and potentiated chemotherapy-induced apoptosis. Our studies provide

a rationale for targeting PKC isoforms in NSCLC cells, especially PKC δ .

L4 ANSWER 17 OF 35 MEDLINE on STN

DUPLICATE 8

AN 2002428799 MEDLINE

DN PubMed ID: 12185584

TI Rho-kinase contributes to diphosphorylation of myosin II regulatory light

chain in nonmuscle cells.

AU Ueda Kozue; Murata-Hori Maki; Tatsuka Masaaki; Hosoya Hiroshi

CS Department of Biological Science, Graduate School of Science, Hiroshima

University, Higashi-Hiroshima, 739-8526, Japan.

SO Oncogene, (2002 Aug 29) 21 (38) 5852-60.

Journal code: 8711562. ISSN: 0950-9232.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200209

ED Entered STN: 20020820

Last Updated on STN: 20020906

Entered Medline: 20020905

AB **Phosphorylation** of myosin II regulatory light chain (MRLC) is important for cell motility and cytokinesis in nonmuscle cells.

Although

the regulation of monophosphorylated MRLC at serine 19 throughout the cell

cycle was examined in detail, MRLC diphosphorylation at both threonine 18

and serine 19 is still unclear. Here we found that Rho-kinase has an

activity for MRLC diphosphorylation in nonmuscle cells using sequential

column chromatographies. **Transfection** of Rho-kinase

-EGFP induced the excess diphosphorylated MRLC and the bundling of the

actin filaments. Conversely, the treatment of cells with a specific

inhibitor of Rho-kinase, Y-27632, resulted in the decrease of endogenous diphosphorylated MRLC and actin stress fibers.

Immunolocalization studies showed that both diphosphorylated MRLC and

Rho-kinase accumulated and colocalized at the contractile ring and the

midbody in dividing cells. Taken together, it is suggested that

Rho-kinase contributes to MRLC diphosphorylation and reorganization of

actin filaments in nonmuscle cells.

L4 ANSWER 18 OF 35 MEDLINE on STN

DUPLICATE 9

AN 2002299672 MEDLINE

DN PubMed ID: 11956320

TI Leukotriene D(4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells.

AU Parachuri Sailaja; Hallberg Bengt; Juhas Maria; Larsson Christer; Sjolander Anita

CS Division of Experimental Pathology, Department of Laboratory Medicine,

Lund University, University Hospital Malmo, SE-205 02 Malmo, Sweden.

SO Journal of cell science, (2002 May 1) 115 (Pt 9) 1883-93.

Journal code: 0052457. ISSN: 0021-9533.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200212

ED Entered STN: 20020604

Last Updated on STN: 20021217

Entered Medline: 20021211

AB We have recently shown that leukotriene D(4) (LTD(4)) increases cell

survival in intestinal epithelial cells. Here we report and explore the complementary finding that LTD(4) also enhances proliferation in these cells. This proliferative response was approximately half of that induced by epidermal growth factor (EGF) and its required activation of protein kinase C (PKC), Ras and the mitogen-activated protein kinase (MAPK) Erk-1/2. EGF also activated Erk-1/2 in these cells; however the EGF-receptor inhibitor PD153035 did not affect the LTD(4)-induced activation of Erk-1/2. In addition, LTD(4) did not induce **phosphorylation** of the EGF receptor, nor did pertussis toxin (PTX) block EGF-induced activation of Erk-1/2, thus refuting a possible crosstalk between the receptors. Furthermore, LTD(4)-induced, but not EGF-induced, activation of Erk-1/2 was sensitive to PTX, PKC inhibitors and downregulation of PKCepsilon. A definite role for PKCepsilon in LTD(4)-induced stimulation of Erk-1/2 was documented by the inability of LTD(4) to activate Erk-1/2 in cells transfected with either the regulatory domain of PKCepsilon (an isoform specific dominant-negative **inhibitor**) or a **kinase**-dead PKCepsilon. Although Ras and Raf-1 were both transiently activated by LTD(4), only Raf-1 activation was abolished by abrogation of the PKC signal. Furthermore, the LTD(4)-induced activation of Erk-1/2 was unaffected by transfection with dominant-negative N17 Ras but blocked by **transfection** with **kinase**-dead Raf-1. Consequently, LTD(4) regulates the proliferative response by a distinct Ras-independent, PKCepsilon-dependent activation of Erk-1/2 and a parallel Ras-dependent signaling pathway.

L4 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:240151 CAPLUS

DN 137:88018

TI Atypical protein kinase C ζ as a target for chemosensitization of tumor cells

AU Filomenko, Rodolphe; Poirson-Bichat, Florence; Billerey, Claire; Belon,

Jean-Paul; Garrido, Carmen; Solary, Eric; Bettaieb, Ali

CS INSERM U517, EPHE, Ecole Pratique des Hautes Etudes, IFR, Institut

Federatif de Recherche 10, Faculties of Medicine and Pharmacy, Dijon,

21000, Fr.

SO Cancer Research (2002), 62(6), 1815-1821
CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research
DT Journal

LA English

AB Exposure of tumor cells to cytotoxic agents simultaneously
activates a

variety of intracellular signaling pathways. Some of these
pathways

involve enzymes from the protein kinase C (PKC) family of
serine/threonine

kinases. This family includes isoenzymes that neg. influence
cell death,

whereas other demonstrate an opposite effect. The present study
analyzes

the role of the ζ atypical PKC isoform in tumor cell response to
cytotoxic agents. Using a histone H1 **phosphorylation** assay, we
showed that both tumor necrosis factor α and etoposide activate
PKC ζ in U937 human leukemic cells. Stable **transfection** of
a **kinase**-dead, dominant-neg. PKC ζ mutant in U937 cells
decreases Bcl-2 expression while increasing the expression of

Bax and

several procaspases. This transfection also prevents

etoposide-induced

nuclear factor- κ B nuclear translocation and accumulation of

X-linked

inhibitor of apoptosis protein. PKC ζ inhibition accelerates the
occurrence of apoptosis in leukemic cells exposed to etoposide

and tumor

necrosis factor α . This sensitization was confirmed in vitro

by use

of a clonogenic assay. In addition, PKC ζ inhibition sensitized

tumor

cells grown in nude mice to etoposide. These results indicate

that

PKC ζ isoform is a protective signals that is activated in tumor

cells

exposed to a cytotoxic agent. This inducible resistance factor

thus

appears an attractive target for chemosensitization of tumor

cells.

RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 35 BIOSIS COPYRIGHT (c) 2005 The Thomson
Corporation on
STN

AN 2002:353785 BIOSIS

DN PREV200200353785

TI Participation of the CaM-kinases in oxidant-induced I-kappaB
phosphorylation in human T lymphocytes.

AU Howe, Christopher J. [Reprint author]; LaHair, Michelle M. [Reprint author]; Maxwell, Jill A. [Reprint author]; Lee, John T. [Reprint author]; Robinson, Penni J. [Reprint author]; Rodriguez-Mora, Oswaldo [Reprint author]; McCubrey, James A. [Reprint author]; Franklin, Richard A. [Reprint author]

CS Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, 600 Moyer Blvd., Greenville, NC, 27858, USA

SO FASEB Journal, (March 20, 2002) Vol. 16, No. 4, pp. A316. print. Meeting Info.: Annual Meeting of the Professional Research Scientists on Experimental Biology. New Orleans, Louisiana, USA. April 20-24, 2002. CODEN: FAJOEC. ISSN: 0892-6638.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 26 Jun 2002
Last Updated on STN: 26 Jun 2002

AB Cells can be exposed to endogenous oxidants, oxidants produced by nearby cells, or oxidants induced by certain drugs. Oxidative stress is known to induce the activation of NF-kappaB, an important transcription factor that has roles in inflammation, oncogenesis, apoptosis, and viral replication. We report that the calmodulin antagonist W-7 and the CaM-kinase inhibitors, KN-93 and K252a, block oxidative stress-induced I-kappaB phosphorylation in Jurkat T lymphocytes. In addition, we report that transient transfection of a kinase-dead CaM-KIV construct inhibits I-kappaB phosphorylation in response to oxidative stress. Akt, a reported IkappaK kinase, was phosphorylated on T308 in response to oxidative stress and this phosphorylation was sensitive to KN-93 inhibition. This result indicates that the CaM-kinases may be upstream of Akt in this pathway. These findings demonstrate that the CaM-kinases have a role in oxidative stress-induced I-kappaB phosphorylation and identify the CaM-kinases and possibly Akt as potential targets that can be used to minimize NF-kappaB activation in response to oxidative stress.

STN
AN 2002:313340 BIOSIS
DN PREV200200313340
TI Src kinase mediates phosphoinositide 3-kinase/Akt dependent rapid endothelial nitric oxide synthase activation by estrogen.
AU Haynes, M. Page [Reprint author]; Li, Lei [Reprint author]; Sinha, Diviya [Reprint author]; Russell, Kerry [Reprint author]; Collinge, Mark [Reprint author]; Sessa, William; Bender, Jeffrey [Reprint author]
CS Cardiovascular Medicine, Yale University School of Medicine, 295 Congress Ave, New Haven, CT, 06536, USA
SO FASEB Journal, (March 20, 2002) Vol. 16, No. 4, pp. A206. print. Meeting Info.: Annual Meeting of the Professional Research Scientists on Experimental Biology. New Orleans, Louisiana, USA. April 20-24, 2002.
CODEN: FAJOEC. ISSN: 0892-6638.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 29 May 2002
Last Updated on STN: 29 May 2002
AB 17beta-estradiol (E2) activates eNOS, enhancing NO release from endothelial cells via the PI3-kinase/Akt pathway. The upstream regulators of this pathway are unknown. We now demonstrate that the Src family **kinase specific inhibitor** PP2 abrogates E2- but not ionomycin-stimulated NO release. PP2 blocked E2-induced Akt **phosphorylation**, but did not inhibit NO release from cells transduced with a constitutively active Akt. Additionally, PP2 abrogated E2-induced production of PI3-kinase generated-phosphoinositides indicating that the PP2-inhibitable kinase is upstream of PI3-kinase and Akt. A demonstrated estrogen receptor-c-Src association correlated with rapid E2-induced c-Src **phosphorylation**. Moreover, **transfection** of a **kinase-dead** Src inhibited E2 induced Akt **phosphorylation** whereas constitutively active Src stimulated increased basal Akt **phosphorylation**. Collectively, these data demonstrate that E2 rapidly activates Src kinase resulting in successive activation of PI3-kinase, Akt and eNOS with consequent enhanced NO release. This implicates Src kinase as an important upstream regulator of the E2-stimulated endothelial PI3-kinase/Akt/eNOS pathway.

L4 ANSWER 22 OF 35 MEDLINE on STN DUPLICATE 10
 AN 2001696978 MEDLINE
 DN PubMed ID: 11746737
 TI Antiapoptotic and cytotoxic properties of delta opioid peptide
 [D-Ala(2),D-Leu(5)]enkephalin in PC12 cells.
 AU Hayashi Teruo; Tsao Li-I; Su Tsung-Ping
 CS Cellular Pathobiology Unit, Intramural Research Program, National
 Institute on Drug Abuse, National Institutes of Health,
 Baltimore,
 Maryland 21224, USA.
 SO Synapse (New York, N.Y.), (2002 Jan) 43 (1) 86-94.
 Journal code: 8806914. ISSN: 0887-4476.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200201
 ED Entered STN: 20011218
 Last Updated on STN: 20020128
 Entered Medline: 20020124
 AB The delta opioid peptide [D-Ala(2),D-Leu(5)]enkephalin (DADLE)
 has been
 shown to promote organ survival and to protect against
 methamphetamine-induced neurodegeneration. However, the cellular
 mechanisms of these actions of DADLE are not totally clear. We
 examined
 the action of DADLE in serum-deprived pheochromocytoma cells
 (PC12) and
 found that DADLE protected against cell death in those cells.
 However,
 the dose-response curves of the protective effects of DADLE are
 U-shaped
 as judged by three biochemical or morphological assays: the LDH
 release,
 the DNA laddering, and the apoptotic nuclei. It was found that
 femtomolar
 to picomolar concentrations of DADLE are antiapoptotic, whereas
 micromolar
 concentrations of DADLE are cytotoxic in PC12 cells. The
 protective
 effect of DADLE could be attenuated by a selective delta2 opioid
 antagonist and the cytotoxic action of DADLE was reduced by a
 selective mu
 opioid receptor antagonist. The treatment of cells with
 PD98059, a
 selective **inhibitor** of ERK **kinase** (MEK), or the
transfection of cells with a dominant interfering form of MEK
 (MEK-KA97) blocked both the protective effect of DADLE and the
 ERK
phosphorylation induced by DADLE. Cytotoxic concentrations of
 DADLE, on the other hand, caused an increase of Fas-ligand
 (FasL) in PC12

cells that was attenuated by a selective mu antagonist. Our results suggest, therefore, that endogenous opioid peptides may, at low concentrations, promote cell survival via the MEK-ERK pathway perhaps through delta2 opioid receptors, whereas they may kill cells at high concentrations via the activation of FasL through an as-yet unknown mechanism involving mu opioid receptors.
Copyright 2001 Wiley-Liss, Inc.

L4 ANSWER 23 OF 35 MEDLINE on STN DUPLICATE 11
 AN 2001512003 MEDLINE
 DN PubMed ID: 11445585
 TI Atypical lambda/iota PKC conveys 5-lipoxygenase/leukotriene B4-mediated cross-talk between phospholipase A2s regulating NF-kappa B activation in response to tumor necrosis factor-alpha and interleukin-1beta.
 AU Anthonsen M W; Andersen S; Solhaug A; Johansen B
 CS UNIGEN Center for Molecular Biology, Faculty of Chemistry and Biology,
 Norwegian University of Science and Technology, N-7491
 Trondheim, Norway.
 SO Journal of biological chemistry, (2001 Sep 21) 276 (38) 35344-51.
 Electronic Publication: 2001-07-09.
 Journal code: 2985121R. ISSN: 0021-9258.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200110
 ED Entered STN: 20010918
 Last Updated on STN: 20030105
 Entered Medline: 20011025
 AB The transcription factor nuclear factor kappaB (NF-kappaB) plays crucial roles in a wide variety of biological functions such as inflammation, stress, and immune responses. We have shown previously that secretory nonpancreatic (snp) and cytosolic (c) phospholipase A(2) (PLA(2)) regulate NF-kappaB activation in response to tumor necrosis factor (TNF)-alpha or interleukin (IL)-1beta activation and that a functional coupling mediated by the 5-lipoxygenase (5-LO) metabolite leukotriene B(4) (LTB(4)) exists between snpPLA(2) and cPLA(2) in human keratinocytes. In this study, we

have further investigated the mechanisms of PLA(2)-modulated NF-kappaB activation with respect to specific kinases involved in TNF-alpha/IL-1beta-stimulated cPLA(2) **phosphorylation** and NF-kappaB activation. The protein **kinase C** (PKC) **inhibitors** RO 31-8220, Go 6976, and a pseudosubstrate peptide inhibitor of atypical PKCs attenuated arachidonic acid release, cPLA(2) **phosphorylation**, and NF-kappaB activation induced by TNF-alpha or IL-1beta, thus indicating atypical PKCs in cPLA(2) regulation and transcription factor activation. **Transfection** of a **kinase**-inactive mutant of lambda/iotaPKC in NIH-3T3 fibroblasts completely abolished TNF-alpha/IL-1beta-stimulated cellular arachidonic acid release and cPLA(2) activation assayed in vitro, confirming the role of lambda/iotaPKC in cPLA(2) regulation. Furthermore, lambda/iotaPKC and cPLA(2) **phosphorylation** was attenuated by phosphatidylinositol 3-**kinase** (PI3-**kinase**) **inhibitors**, which also reduced NF-kappaB activation in response to TNF-alpha and IL-1beta, indicating a role for PI3-kinase in these processes in human keratinocytes. TNF-alpha- and IL-1beta-induced **phosphorylation** of lambda/iotaPKC was attenuated by inhibitors toward snpPLA(2) and 5-LO and by an LTB(4) receptor antagonist, suggesting lambda/iotaPKC as a downstream effector of snpPLA(2) and 5-LO/LTB(4) the LTB(4) receptor. Hence, lambda/iotaPKC regulates snpPLA(2)/LTB(4)-mediated cPLA(2) activation, cellular arachidonic acid release, and NF-kappaB activation induced by TNF-alpha and IL-1beta. In addition, our results demonstrate that PI3-kinase and lambda/iotaPKC are involved in cytokine-induced cPLA(2) and NF-kappaB activation, thus identifying lambda/iotaPKC as a novel regulator of cPLA(2).

L4 ANSWER 24 OF 35 MEDLINE on STN

AN 2001189665 MEDLINE

DN PubMed ID: 11280762

TI Stimulation of beta1 integrin down-regulates ICAM-1 expression and

ICAM-1-dependent adhesion of lung cancer cells through focal adhesion kinase.

AU Yasuda M; Tanaka Y; Tamura M; Fujii K; Sugaya M; So T; Takenoyama M; Yasumoto K

CS Second Department of Surgery, School of Medicine, University of
 Occupational and Environmental Health, Japan, Kitakyushu.
 SO Cancer research, (2001 Mar 1) 61 (5) 2022-30.
 Journal code: 2984705R. ISSN: 0008-5472.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200104
 ED Entered STN: 20010425
 Last Updated on STN: 20010425
 Entered Medline: 20010419
 AB Adhesion molecules are involved in intracellular signaling in
 various
 physiological and pathological processes including metastasis
 and growth
 of tumor cells. Tumor cells interact with various host cells as
 well as
 with extracellular matrices through certain adhesion molecules
 such as
 integrins. We here propose that stimulation of beta1 integrin
 reduces
 intercellular adhesion molecule (ICAM)-1-mediated interaction of
 lung
 cancer cells with CTLs. This concept is based on the following
 findings:
 (a) engagement of beta1 integrins on certain lung cancer cells
 by a
 specific antibody or by ligand matrices such as fibronectin and
 collagen
 markedly reduced ICAM-1 expression on the cell surface and
 induced
 sICAM-1; (b) down-regulation of ICAM-1 by stimulation of beta1
 integrins
 was abrogated by tyrosine **kinase inhibitors** or by
transfection of dominant negative truncations of focal adhesion
 kinase (FAK); (c) engagement of beta1 integrins also reduced
 ICAM-1-dependent adhesion of lung cancer cells to T cells, a
 process
 completely inhibited by tyrosine **kinase inhibitors** and
 by **transfection** of dominant negative forms of FAK; and (d)
 stimulation of beta1 integrins prevented killing of lung cancer
 cells by
 autologous CTLs. In malignant tumors, cancer cells, including
 lung cancer
 cells, are surrounded by extracellular matrix proteins such as
 fibronectin
 and collagen. This suggests that the engagement of beta1
 integrins by
 matrix proteins potentially occurs in cancer cells in vivo and
 that
 continuous stimulation via beta1 integrins reduces
 ICAM-1-expression,

ICAM-1-mediated adhesion of cancer cells to CTLs and their killing by CTLs. Our results suggest that such processes can lead to the escape of lung cancer cells in vivo from immunological surveillance.

L4 ANSWER 25 OF 35 MEDLINE on STN DUPLICATE 12
AN 2001514866 MEDLINE
DN PubMed ID: 11562449
TI D(4) dopamine receptor differentially regulates Akt/nuclear factor-kappa b and extracellular signal-regulated kinase pathways in D(4)MN9D cells.
AU Zhen X; Zhang J; Johnson G P; Friedman E
CS Laboratory of Molecular Pharmacology, Department of Pharmacology and Physiology, MCP Hahnemann School of Medicine, Philadelphia, Pennsylvania, USA.
NC DA11029 (NIDA)
NS29514 (NINDS)
SO Molecular pharmacology, (2001 Oct) 60 (4) 857-64.
Journal code: 0035623. ISSN: 0026-895X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200110
ED Entered STN: 20010920
Last Updated on STN: 20011008
Entered Medline: 20011004
AB The present study was designed to investigate the role of D(4) dopamine receptors in regulating the Akt/nuclear factor-kappa B (NF-kappa B) and extracellular signal-regulated kinase (ERK) signaling pathways. The D(4) dopamine receptor agonist PD168077 induced time- and dose-dependent activation of Akt and ERK in D(4)MN9D cells that stably express D(4) dopamine receptors. Maximal Akt and ERK stimulation was achieved at 1 microM PD168077. The agonist-mediated stimulations of Akt and ERK were abolished when cells were preincubated with 50 ng/ml PTX or with 1 microM L745,870, a D(4) dopamine receptor antagonist, indicating that activation of the Akt or ERK pathways is mediated by D(4) dopamine receptors and require a pertussis toxin-sensitive G protein. We also detected a time-

and dose-dependent activation of NF-kappa B. Activation of NF-kappa B by 1 microM PD168077 was attenuated in D(4)MN9D cells that were transfected with a kinase-deficient Akt but not in cells transfected with a dominant negative Ras (N17Ras), suggesting that NF-kappa B activation requires Akt but is independent of Ras. In contrast, the transfection of N17Ras into D(4)MN9D cells blunted D(4) dopamine receptor-mediated ERK activation, indicating a Ras-dependent mechanism. Moreover, PP2 (20 nM), an inhibitor of Src, blocked D(4) receptor-mediated SHC **phosphorylation** and ERK activation. In contrast, **transfection of a kinase** -dead Akt did not alter D(4) receptor-stimulated ERK. However, PP2 and the mitogen activated protein **kinase kinase inhibitor** PD98059 did not change D(4) receptor-mediated Akt/NF-kappa B activation. All these indicate that distinct mechanisms mediate ERK and Akt/NF-kappa B activation by D(4) dopamine receptor stimulation. We also demonstrated that D(4) receptor-stimulated cell proliferation is mediated by the Src/SHC/Ras/ERK pathway.

L4 ANSWER 26 OF 35 MEDLINE on STN DUPLICATE 13
 AN 2001378723 MEDLINE
 DN PubMed ID: 11435224
 TI Activation of the EGF receptor signaling pathway in airway epithelial cells exposed to Utah Valley PM.
 AU Wu W; Samet J M; Ghio A J; Devlin R B
 CS Center for Environmental Medicine and Lung Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
 SO American journal of physiology. Lung cellular and molecular physiology, (2001 Aug) 281 (2) L483-9.
 Journal code: 100901229. ISSN: 1040-0605.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200108
 ED Entered STN: 20010813
 Last Updated on STN: 20010813
 Entered Medline: 20010809
 AB Exposure to ambient particulate matter (PM) in the Utah Valley has

previously been associated with a variety of adverse health effects. To investigate intracellular signaling mechanisms for pulmonary responses to Utah Valley PM inhalation, human primary airway epithelial cells were exposed to aqueous extracts of PM collected from the year before (Y1), during (Y2), and after (Y3) the closure of a local steel mill located in the Utah Valley in this study. **Transfection** with **kinase**-deficient extracellular signal-regulated kinase (ERK) 1 constructs partially blocked Utah Valley PM-induced interleukin (IL)-8 promoter reporter activity. The mitogen-activated protein kinase/ERK **kinase** (MEK) activity **inhibitor** PD-98059 significantly abolished IL-8 released in response to Utah Valley PM, as did the epidermal growth factor (EGF) receptor **kinase inhibitor** AG-1478. Western blotting showed that Utah Valley PM induced **phosphorylation** of EGF receptor tyrosine, MEK1/2, and ERK1/2, which could be ablated with AG-1478 or PD-98059. For all findings, the potency of Utah Valley PM collected during Y2 was found to be lower relative to that of Y1 and Y3. These data demonstrate that Utah Valley PM can induce IL-8 expression partially through the activation of the EGF receptor signaling.

L4 ANSWER 27 OF 35 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

AN 2001290758 EMBASE

TI Activation of the EGF receptor signaling pathway in airway epithelial

cells exposed to Utah Valley PM.

AU Wu W.; Samet J.M.; Ghio A.J.; Devlin R.B.

CS R.B. Devlin, Human Studies Division, National Health Research Laboratory,

US Environmental Protection Agency, Research Triangle Park, NC 27711,

United States. devlin.robert@epa.gov

SO American Journal of Physiology - Lung Cellular and Molecular Physiology,

(2001) Vol. 281, No. 2 25-2, pp. L483-L489.

Refs: 26

ISSN: 1040-0605 CODEN: APLPE7

CY United States

DT Journal; Article

FS 005 General Pathology and Pathological Anatomy

015 Chest Diseases, Thoracic Surgery and Tuberculosis
029 Clinical Biochemistry
037 Drug Literature Index

LA English

SL English

ED Entered STN: 20010906

Last Updated on STN: 20010906

AB Exposure to ambient particulate matter (PM) in the Utah Valley
has

previously been associated with a variety of adverse health
effects. To

investigate intracellular signaling mechanisms for pulmonary
responses to

Utah Valley PM inhalation, human primary airway epithelial cells
were

exposed to aqueous extracts of PM collected from the year before
(Y1),

during (Y2), and after (Y3) the closure of a local steel mill
located in

the Utah Valley in this study. **Transfection** with **kinase**
-deficient extracellular signal-regulated kinase (ERK) 1
constructs

partially blocked Utah Valley PM-induced interleukin (IL)-8
promoter

reporter activity. The mitogen-activated protein kinase/ERK
kinase (MEK) activity **inhibitor** PD-98059 significantly
abolished IL-8 released in response to Utah Valley PM, as did the
epidermal growth factor (EGF) receptor **kinase inhibitor**
AG-1478. Western blotting showed that Utah Valley PM induced
phosphorylation of EGF receptor tyrosine, MEK1/2, and ERK1/2,
which could be ablated with AG-1478 or PD-98059. For all

findings, the

potency of Utah Valley PM collected during Y2 was found to be
lower

relative to that of Y1 and Y3. These data demonstrate that Utah
Valley PM

can induce IL-8 expression partially through the activation of
the EGF

receptor signaling.

L4 ANSWER 28 OF 35 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS
RESERVED.

on STN

AN 2000157170 EMBASE

TI Serine residues 994 and 1023/25 are important for insulin
receptor kinase

inhibition by protein kinase C isoforms $\beta 2$ and θ .

AU Strack V.; Hennige A.M.; Krutzfeldt J.; Bossenmaeir B.; Klein
H.-H.;

Kellerer M.; Lammers R.; Haring H.-U.

CS Dr. H.-U. Haring, Eberhard-Karls-Universitat, Abt. Innere
Medizin IV,

Otfried-Muller-Str. 10, D-72076 Tübingen, Germany

SO Diabetologia, (2000) Vol. 43, No. 4, pp. 443-449.
 Refs: 39
 ISSN: 0012-186X CODEN: DBTGAJ

CY Germany
 DT Journal; Article
 FS 003 Endocrinology
 029 Clinical Biochemistry

LA English
 SL English
 ED Entered STN: 20000518
 Last Updated on STN: 20000518

AB Aims/hypothesis. Inhibition of the signalling function of the human insulin receptor (HIR) is one of the principle mechanisms which induce cellular insulin resistance. It is speculated that serine residues in the insulin receptor β -subunit are involved in receptor inhibition either as inhibitory **phosphorylation** sites or as part of receptor domains which bind inhibitory proteins or tyrosine phosphatases.

As reported earlier we prepared 16 serine to alanine point mutations of the HIR and found that serine to alanine mutants HIR-994 and HIR-1023/25 showed increased tyrosine autophosphorylation when expressed in human embryonic kidney (HEK) 293 cells. In this study we examined whether these mutant receptors have a different susceptibility to inhibition by serine kinases or an altered tyrosine kinase activity. Methods. Tyrosine **kinase** assay and **transfection** studies. Results. In an in vitro kinase assay using IRS-1 as a substrate we could detect a higher intrinsic tyrosine kinase activity of both receptor constructs. Additionally, a higher capacity to phosphorylate the adapter protein Shc in intact cells was seen. To test the inhibition by serine kinases, the receptor constructs were expressed in HEK 293 cells together with IRS-1 and protein kinase C isoforms $\beta 2$ and θ . Phorbol ester stimulation of these cells reduced wild-type receptor autophosphorylation to 58% or 55% of the insulin simulated state, respectively. This inhibitory effect was not observed with HIR-994 and HIR-1023.25, although all other tested HIR mutants showed similar inhibition induced by protein

kinase C. Conclusion/interpretation. The data suggest that the HIR-domain which contains the serine residues 994 and 1023/25 is important for the inhibitory effect of protein kinase C isoforms $\beta 2$ and θ on insulin receptor autophosphorylation.

L4 ANSWER 29 OF 35 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.

on STN

AN 1999201897 EMBASE

TI **Phosphorylation** of the transactivation domain of Pax6 by extracellular signal-regulated kinase and p38 mitogen-activated protein

kinase.

AU Mikkola I.; Bruun J.-A.; Bjorkoy G.; Holm T.; Johansen T.

CS T. Johansen, Dept. of Biochemistry, Institute of Medical Biology, University of Tromso, 9037 Tromso, Norway. terjej@fagmed.uit.no

SO Journal of Biological Chemistry, (21 May 1999) Vol. 274, No. 21, pp.

15115-15126.

Refs: 76

ISSN: 0021-9258 CODEN: JBCHA3

CY United States

DT Journal; Article

FS 029 Clinical Biochemistry

LA English

SL English

ED Entered STN: 19990701

Last Updated on STN: 19990701

AB The transcription factor Pax6 is required for normal development of the

central nervous system, the eyes, nose, and pancreas. Here we show that

the transactivation domain (TAD) of zebrafish Pax6 is phosphorylated in

vitro by the mitogen-activated protein kinases (MAPKs) extracellular-signal regulated kinase (ERK) and p38 kinase but not by Jun

N-terminal kinase (JNK). Three of four putative proline-dependent kinase

phosphorylation sites are phosphorylated in vitro. Of these sites, the serine 413 (Ser413) is evolutionary conserved from sea urchin

to man. Ser413 is also phosphorylated in vivo upon activation of ERK or

p38 kinase. Substitution of Ser413 with alanine strongly decreased the

transactivation potential of the Pax6 TAD whereas substitution with

glutamate increased the transactivation. Reporter gene assays with

wild-type and mutant Pax6 revealed that transactivation by the full-length

Pax6 protein from paired domain- binding sites was strongly enhanced (16-fold) following co-**transfection** with activated p38 **kinase**. This enhancement was largely dependent on the Ser413 site. ERK activation, however, produced a 3-fold increase in transactivation which was partly independent of the Ser413 site. These findings provide a starting point for further studies aimed at elucidating a post-translational regulation of Pax6 following activation of MAPK signaling pathways.

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:725451 CAPLUS

DN 132:30447

TI Transfection of an inducible p16/CDKN2A construct mediates reversible

growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line

AU Frost, Simon J.; Simpson, David J.; Clayton, Richard N.; Farrell, William E.

CS Centre for Cell and Molecular Medicine School of Postgraduate Medicine,
North Staffordshire Hospital, Keele University, Stoke-on-Trent,
ST4 7QB,
UK

SO Molecular Endocrinology (1999), 13(11), 1801-1810
CODEN: MOENEN; ISSN: 0888-8809

PB Endocrine Society

DT Journal

LA English

AB Recent studies have shown that methylation of the CpG island within the p16/CDKN2A gene is associated with an absence of p16 protein in human pituitary tumors. However, the effect of restoration of p16 protein expression in this tumor type has not been investigated. In the absence of an available human pituitary cell line we first assessed the suitability of the mouse corticotroph cell line AtT20 as a model system. Initial expts. showed that the p16/CDKN2A gene was not expressed, whereas a transcript for RB1 was detected as assessed by RT-PCR. Further studies showed the p16/CDKN2A gene to be homozygously deleted. The absence of p16/CDKN2A and presence of RB1, the downstream effector of p16-mediated

cell cycle arrest confirmed the suitability of the AtT20 cell line as a model system. Stable transfectants were generated in which p16/CDKN2A is regulated by an inducible promoter. The regulatory effects of p16/CDKN2A expression on cell proliferation were assessed and complemented by fluorescence-activated cell sorting (FACS) anal. of cell cycle profile. Induced expression of p16/CDKN2A resulted in a profound inhibition of cell growth and G1 arrest (80-82%). Western blot anal. showed concomitant expression of p16 protein in arrested cells and a shift in the **phosphorylation** status of pRB toward its hypophosphorylated form. To further confirm that expression of p16/CDKN2A mimicked its in vivo role, reversibility was assessed using alternate cycles in the presence and absence of inducer (isopropyl-1-thio- β -D-galactopyranoside). Over three cycles the absence of induced expression of p16/CDKN2A resulted in release from G1 arrest. These results show that, in a pituitary cell line model, restoration of p16 expression is indeed sufficient to arrest cells in G1 and inhibit cell proliferation and is reversible. Thus restoration of p16 expression through novel strategies, including gene therapy or demethylating agents, may offer successful therapeutic intervention in human forms of this disease.

RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 35 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on

STN

AN 1998:343922 BIOSIS

DN PREV199800343922

TI Applied pressure enhances cell proliferation through mitogen-activated

protein kinase activation in mesangial cells.

AU Kawata, Yasunobu; Mizukami, Yoichi [Reprint author]; Fujii, Zenzo;

CS Sakumura, Toshihiro; Yoshida, Ken-Ichi; Matsuzaki, Masunori
Dep. Legal Med., Yamaguchi Univ. Sch. Med., 1144 Kogushi, Ube, Yamaguchi

755-8505, Japan

SO Journal of Biological Chemistry, (July 3, 1998) Vol. 273, No. 27, pp.

16905-16912. print.

CODEN: JBCHA3. ISSN: 0021-9258.

DT Article

LA English

ED Entered STN: 13 Aug 1998

Last Updated on STN: 10 Sep 1998

AB Progressive renal diseases lead to prolonged glomerular hypertension,

which induces the proliferation of mesangial cells. This proliferation is

thought to be involved in the development of renal injury. Here we

investigate mitogen-activated protein kinase (MAPK) activation and cell

proliferation in mesangial cells under conditions of high pressure. After

pressure-load, the **phosphorylation** level of MAPK (at Tyr-204) increases rapidly with a peak at 1 min, although the amount of MAPK

remains almost constant during pressure-load. To confirm the activation

of MAPK, we carried out an immunoprecipitation-kinase assay. MAPK

activity during pressure-load shows kinetics similar to that of the

tyrosine **phosphorylation**. In contrast, c-Jun N-terminal kinase 1 (JNK1) **phosphorylation** falls below basal levels in response to high pressure. Immunocytochemical observations show phosphorylated MAPK

in the nucleus at 10 min. The expression of c-Fos, a nuclear transcription factor, is induced by high pressure, and the induction is

significantly inhibited by PD98059 (50 μ M), an upstream MAPK/extracellular signal-regulated **kinase kinase**

(MEK) **inhibitor** of MAPK. The expression of the c-Jun that is induced by JNK1 activation remains unchanged during pressure-load. MAPK

phosphorylation and cell proliferation by applied pressure are significantly inhibited by genistein, a tyrosine **kinase inhibitor** in a dose-dependent manner, but not by protein **kinase C inhibitors**, chelerythrine and GF109203X.

Genistein also blocks pressure-induced tyrosine **phosphorylation** of proteins with molecular masses of 35, 53, and 180 kDa. To clarify the

physiological role in MAPK activation under high pressure conditions, we

transfected antisense MAPK DNA into mesangial cells. The antisense DNA (2

μ M) inhibited MAPK expression by 80% compared with expression in the

presence of sense or scrambled DNA, and significantly blocked pressure-induced cell proliferation. Treatment of cells with MEK

inhibitor also produced a similar result. MEK inhibitor strongly suppresses DNA synthesis induced by pressure-load. Cyclin D1 expression is significantly increased under high pressure conditions, and the increase is blocked by treatment with MEK inhibitor. These findings show that pressure-load, a novel activator of MAPK, induces the activation of tyrosine kinases, and enhances the proliferation of mesangial cells, probably through cyclin D1 expression.

L4 ANSWER 32 OF 35 MEDLINE on STN DUPLICATE 14
AN 1998417294 MEDLINE
DN PubMed ID: 9746212
TI cAMP-dependent **phosphorylation** and hexamethylene-bis-acetamide induced dephosphorylation of p19 in murine erythroleukemia cells.
AU Scheele J S
CS Department of Chemistry and Biochemistry, University of California San Diego, La Jolla 92093-0612, USA.
SO Molecular and cellular biochemistry, (1998 Aug) 185 (1-2) 55-63.

Journal code: 0364456. ISSN: 0300-8177.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199905
ED Entered STN: 19990607
Last Updated on STN: 19990607
Entered Medline: 19990524
AB The objective of this study was to investigate cyclic-adenosinemonophosphate (cAMP)-dependent **phosphorylation** in murine erythroleukemia (MEL) cells and to identify either direct substrates of cAMP-dependent kinase or downstream effectors of cAMP dependent **phosphorylation** with a potential function in growth and differentiation. MEL-cells rendered deficient in cAMP-dependent protein kinase (A-kinase) activity by stable **transfection** with DNA encoding for either a mutant regulatory subunit or a specific peptide **inhibitor** of A-Kinase (PKI) are unable to differentiate normally in response to chemical inducers. We have identified by 2-D Western blotting 2 phosphorylated forms of p19, a highly conserved 18-19 kDa cytosolic protein that is frequently upregulated in transformed cells and undergoes

phosphorylation in mammalian cells upon activation of several signal transduction pathways. The **phosphorylation** of the more acidic phosphorylated form is increased in a cAMP-dependent fashion and impaired in cells deficient in cAMP-dependent kinase (A-kinase). Treatment of MEL-cells with the chemical inducer of differentiation hexamethylene-bisacetamide (HMBA) led to dephosphorylation of this phosphoform. Our data are compatible with previous observations which imply that **phosphorylation** of Ser 38 in p19 by p34cdc2-kinase leads to a more basic phosphoform and simultaneous phosphorylation by mitogen-activated kinase of Ser 25 in response to protein kinase C and the cAMP-dependent kinase creates the more acidic species.

L4 ANSWER 33 OF 35 MEDLINE on STN DUPLICATE 15
 AN 97042354 MEDLINE
 DN PubMed ID: 8887554
 TI FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2.
 AU Tan Y; Rouse J; Zhang A; Cariati S; Cohen P; Comb M J
 CS Cell Signaling Laboratory, New England Biolabs, Beverly, MA 01915, USA.
 SO EMBO journal, (1996 Sep 2) 15 (17) 4629-42.
 Journal code: 8208664. ISSN: 0261-4189.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199701
 ED Entered STN: 19970128
 Last Updated on STN: 20000303
 Entered Medline: 19970102
 AB Fibroblast growth factor (FGF) activates a protein kinase cascade in SK-N-MC cells that regulates gene expression at a cyclic-AMP response element (CRE) by stimulating the transcriptional activity of CREB. The activation of CREB is prevented by a dominant negative mutant of Ras and triggered via the same site (Ser133) that becomes phosphorylated in response to cyclic AMP and Ca²⁺. However, the effect of FGF is not mediated by cyclic AMP-dependent protein kinase, TPA-sensitive isoforms of protein kinase-C, p70S6K or p90rsk (all of which phosphorylate CREB at

Ser133 in vitro). Instead, we identify the FGF-stimulated CREB kinase as MAP kinase-activated protein (MAPKAP) kinase-2, an enzyme that lies immediately downstream of p38 MAP kinase, in a pathway that is also stimulated by cellular stresses. We show that MAPKAP kinase-2 phosphorylates CREB at Ser133 in vitro, that the FGF- or stress-induced activation of MAPKAP kinase-2 and **phosphorylation** of CREB and ATF-1 are prevented by similar concentrations of the specific p38 MAP **kinase inhibitor** SB 203580, and that MAPKAP kinase-2 is the only detectable SB 203580-sensitive CREB kinase in SK-N-MC cell extracts. We also show that transfection of RK/p38 MAP kinase in SK-N-MC cells, but not **transfection** of p44 MAP **kinase**, activates Gal4-CREB-dependent transcription via Ser133. These findings identify a new growth factor and stress-activated signaling pathway that regulates gene expression at the CRE.

L4 ANSWER 34 OF 35 MEDLINE on STN DUPLICATE 16
 AN 94253131 MEDLINE
 DN PubMed ID: 8195196
 TI Characterization of Ca²⁺/calmodulin-dependent protein kinase IV. Role in transcriptional regulation.
 AU Enslen H; Sun P; Brickey D; Soderling S H; Klammo E; Soderling T R
 CS Vollum Institute, Oregon Health Sciences University, Portland 97201.
 NC DK44239 (NIDDK)
 GM41292 (NIGMS)
 SO Journal of biological chemistry, (1994 Jun 3) 269 (22) 15520-7. Journal code: 2985121R. ISSN: 0021-9258.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199406
 ED Entered STN: 19940707
 Last Updated on STN: 19980206
 Entered Medline: 19940630
 AB We have characterized Ca²⁺/calmodulin-dependent protein kinase IV (CaM kinase IV), expressed using the baculovirus/Sf9 cell system, to assess its potential role in Ca²⁺-dependent transcriptional regulation. CaM kinase IV was strongly inhibited in vitro by KN-62, a specific CaM kinase

inhibitor which suppresses Ca^{2+} -dependent transcription of several genes, so we tested whether CaM kinase IV could stimulate transcription.

Co-transfection of COS-1 cells by cDNA for CaM kinase IV gave 3-fold

stimulation of a reporter gene expression, whereas co-transfection

with CaM **kinase** II gave no transcriptional stimulation. Since this transcriptional response was mediated by **phosphorylation** of cAMP responsive element-binding protein (CREB), we determined the kinetics

and site specificities of CaM kinases IV and II for phosphorylating CREB

in vitro. CaM kinases IV and II and cAMP kinase (protein kinase A) all

had similar K_m values for CREB (1-5 microns), but the V_{max} of CaM kinase

IV was 40-fold lower than those of CaM kinase II and protein kinase A.

Although all three kinases phosphorylated Ser133 in CREB, CaM kinase II

also gave equal **phosphorylation** of a second site which was not Ser98. The two CREB **phosphorylation** sites were separately ^{32}P -labeled, and the abilities of protein phosphatases 1, 2A, and 2B

(calcineurin) to dephosphorylate them were tested. Our results show that

all three phosphatases could dephosphorylate both sites, and calcineurin

was a stronger catalyst for dephosphorylating site 1 (Ser133) than for

site 2. These results indicate that CaM kinase IV may be important in

Ca^{2+} -dependent transcriptional regulation through **phosphorylation** of Ser133 in CREB. The fact that CaM kinase II phosphorylates another

site in addition to Ser133 in CREB raises the possibility that this second

phosphorylation site may account for the suppressed **phosphorylation** site may account for the suppressed ability of

CaM kinase II to enhance transcription through the CRE/CREB system.

In addition multiple protein phosphatases, including calcineurin, may exert a

modulatory effect on transcription depending on which site they dephosphorylate.

AN 1992:186312 BIOSIS
 DN PREV199293097262; BA93:97262
 TI ISOLATION AND CHARACTERIZATION OF RAT 3Y1 FIBROBLAST CLONES
 OVEREXPRESSION
 THE SRC HOMOLOGY REGION OF PHOSPHOLIPASE C-GAMMA-2.
 AU HOMMA Y [Reprint author]; EMORI Y; TAKENAWA T
 CS DEP BIOL RES, TOKYO METROPOLITAN INST GERONTOL, 35-2 SAKAE,
 ITABASHI,
 TOKYO 173, JPN
 SO Journal of Biological Chemistry, (1992) Vol. 267, No. 6, pp.
 3778-3782.
 CODEN: JBCHA3. ISSN: 0021-9258.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 13 Apr 1992
 Last Updated on STN: 1 Jun 1992
 AB To examine the regulatory function of the src-related SH2 and SH3
 (SH2/SH3) region of phospholipase C- γ 2 (PLC- γ 2), we expressed
 this region of rat PLC- γ 2 cDNA in rat 3Y1 fibroblasts and
 isolated
 and characterized a number of clones (.apprx. 20 clones). An
 increase of
 endogenous tyrosine kinase activity was observed in all cell
 clones that
 highly expressed a translational product of the SH2/SH3 domain.
 Moreover,
 endogenous phosphatidylinositol 4,5-bisphosphate hydrolyzing
 activity was
 also enhanced in these clones, and PLC- γ 1 seemed to be
 preferentially activated among endogenous PLC isozymes.
 Genistein, an
 inhibitor of tyrosine kinase, inhibited this activation
 of PLC- γ 1, and tyrosine phosphorylation was observed on
 PLC- γ 1 molecules, indicating the involvement of tyrosine
 kinases in
 the PLC- γ 1 activation. These results suggest that the SH2/SH3
 region of PLC- γ would function as a multidirectional regulator
 which
 controls at least two major signaling pathways: tyrosine kinase
 and
 phosphatidylinositol 4,5-bisphosphate hydrolysis.

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	65.52	65.73
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.84	-5.84

FILE 'STNGUIDE' ENTERED AT 19:28:08 ON 05 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 1, 2005 (20050701/UP).